- Home
- HTT vs MYGN Comparison
HTT vs MYGN Comparison
Compare HTT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HTT
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
Company Overview
Basic Information| Metric | HTT | MYGN |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.3M | 372.1M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HTT | MYGN |
|---|---|---|
| Price | $2.41 | $4.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 73.7K | ★ 2.0M |
| Earning Date | 05-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.88 | $2.74 |
| 52 Week High | $3.91 | $8.59 |
Technical Indicators
Market Signals| Indicator | HTT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 65.78 |
| Support Level | $2.34 | $4.24 |
| Resistance Level | $2.69 | $4.92 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 13.79 | 91.23 |
Price Performance
Historical ComparisonAbout HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share
High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.